While stem cell therapy “remains in its infancy,” they write, “there are a growing number of cosmetic practitioners that are advertising minimally invasive, stem cell-based rejuvenation procedures.” The article was prompted by “worrying advertisements” claiming benefits of stem cell procedures for facelifts, breast augmentationeven “stem cell vaginal rejuvenation.” These ads claim benefits from procedures that have not undergone rigorous scientific evaluationincluding potential risks related to stem cell and tissue processing and the effects of aging on stem cells. To gain insight into these claims, Dr Longaker and coauthors performed a Biocutis all natural skin care products Google search for cosmetic stem cell treatments, the most common of which was “stem cell facelifts.” Most procedures used “stem cells” isolated from fat. However, the websites provided little information on the quality of the stem cells used. Without advanced cell-sorting procedures, these products used in these procedures likely contain many other types of cells besides fat-derived stem cells. Many clinics also offered plasma-rich platelet protein treatments, which they inaccurately marketed as stem cell therapy. Despite evidence that is “minimal at best,” advertisers are also claiming that their stem cell treatments have “anti-aging effects.” The authors note that procedures marketed as “stem cell facelifts” are often just “lipofilling” proceduresan established fat injection technique with no prolonged anti-aging effect.
For the original version including any supplementary images or video, visit http://www.eurekalert.org/pub_releases/2014-07/wkh-boc072914.php

Fate Therapeutics Secures Up to $20 Million in Debt Financing – Yahoo Finance

Please enter your Phone Number. Send Thanks! A link has been sent. Done Fate Therapeutics Secures Up to $20 Million in Debt Financing Strengthened Cash Position Expected to Fund Company Through 2015 Fate Therapeutics, Inc 53 minutes ago 0 shares Content preferences Done SAN DIEGO, July 31, 2014 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. ( FATE ), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has completed a long-term debt financing of up to $20 million with Silicon Valley Bank.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/fate-therapeutics-secures-20-million-200100802.html